CXCL12 and neoplasm: In vivo, treatment with the CXCR4 antagonist AMD3100 significantly reduced SDF-1+CD206+ macrophage accumulation around tumour vessels after radiotherapy, with increased iNOS+ M1 macrophage and non-differentiated SDF-1+ monocyte populations (Fig. 6h and Supplementary Fig. 13c).